BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 38552564)

  • 21. Effects of Lipid Metabolism-Related Genes PTGIS and HRASLS on Phenotype, Prognosis, and Tumor Immunity in Lung Squamous Cell Carcinoma.
    Lei K; Liang R; Tan B; Li L; Lyu Y; Wang K; Wang W; Wang K; Hu X; Wu D; Lin H; Wang M
    Oxid Med Cell Longev; 2023; 2023():6811625. PubMed ID: 36703911
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High Expression of
    Chen Y; Zhou M; Gu X; Wang L; Wang C
    Dis Markers; 2022; 2022():8789515. PubMed ID: 35855850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
    Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
    Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
    [TBL] [Abstract][Full Text] [Related]  

  • 24. POTEE mutation as a potential predictive biomarker for immune checkpoint inhibitors in lung adenocarcinoma.
    Li Y; Yang Q; Liu Y; Yi H; Ju Y; Qi G
    Invest New Drugs; 2023 Aug; 41(4):556-563. PubMed ID: 37318657
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of downstream signaling cascades of ACK1 and prognostic classifiers in non-small cell lung cancer.
    Zhu J; Liu Y; Zhao M; Cao K; Ma J; Peng S
    Aging (Albany NY); 2021 Jan; 13(3):4482-4502. PubMed ID: 33495411
    [No Abstract]   [Full Text] [Related]  

  • 26.
    Zhang N; Shen J; Gou L; Cao M; Ding W; Luo P; Zhang J
    Bioengineered; 2022 May; 13(5):11577-11592. PubMed ID: 35531878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor mutation burden (TMB)-associated signature constructed to predict survival of lung squamous cell carcinoma patients.
    Yan D; Chen Y
    Sci Rep; 2021 Apr; 11(1):9020. PubMed ID: 33907270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypoxia-related lncRNAs to build prognostic classifier and reveal the immune characteristics of EGFR wild type and low expression of PD-L1 squamous and adenocarcinoma NSCLC.
    Zhao F; Wang M; Zhu J
    Cancer Med; 2021 Sep; 10(17):6099-6113. PubMed ID: 34250747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ERCC6L is a biomarker and therapeutic target for non-small cell lung adenocarcinoma.
    Hou G; Lu Z; Bi Y; Deng J; Yang X
    Med Oncol; 2022 Feb; 39(5):51. PubMed ID: 35150321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Exploring the Role of PCDHGB4 in the Occurrence of Lung Squamous Cell Carcinoma Based on Bioinformatics Analysis].
    Lu R; Abuduhailili X; Li Y; Ning J; Feng Y
    Zhongguo Fei Ai Za Zhi; 2024 Mar; 27(3):199-215. PubMed ID: 38590195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transcriptomic FHIT
    Brisebarre A; Ancel J; Ponchel T; Loeffler E; Germain A; Dalstein V; Dormoy V; Durlach A; Delepine G; Deslée G; Polette M; Nawrocki-Raby B
    Front Immunol; 2022; 13():1058531. PubMed ID: 36544755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
    Hu X; Xu H; Xue Q; Wen R; Jiao W; Tian K
    Mol Med; 2021 Oct; 27(1):126. PubMed ID: 34620079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LINC00628 is differentially expressed between lung adenocarcinoma and squamous cell carcinoma and is associated with the prognosis of NSCLC.
    Liu T; Xu S; Liu X
    Oncol Lett; 2022 Feb; 23(2):55. PubMed ID: 34992687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. KAT2B is an immune infiltration-associated biomarker predicting prognosis and response to immunotherapy in non-small cell lung cancer.
    Zhou X; Wang N; Zhang Y; Yu H; Wu Q
    Invest New Drugs; 2022 Feb; 40(1):43-57. PubMed ID: 34499335
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment.
    Song L; Wang X; Cheng W; Wu Y; Liu M; Liu R; Zhang S; Xia H; Liu H; Tai X; Zhao H; Li X; Ji F
    BMC Pulm Med; 2021 Dec; 21(1):420. PubMed ID: 34923982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated expression of G3BP1 associates with YB1 and p-AKT and predicts poor prognosis in nonsmall cell lung cancer patients after surgical resection.
    Zheng H; Zhan Y; Zhang Y; Liu S; Lu J; Yang Y; Wen Q; Fan S
    Cancer Med; 2019 Nov; 8(16):6894-6903. PubMed ID: 31560169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non‑small cell lung cancer carrying PBRM1 mutation suggests an immunologically cold phenotype leading to immunotherapy failure even with high TMB.
    Miao XY; Wu H; Ye BC; Yi QW; Lin FN; Wang YL; Ren CL; Jiang YF; Li A
    Sci Rep; 2022 Dec; 12(1):20734. PubMed ID: 36456601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification and Validation of a Tumor Microenvironment-Related Gene Signature for Prognostic Prediction in Advanced-Stage Non-Small-Cell Lung Cancer.
    Zhang X; Shi X; Zhao H; Jia X; Yang Y
    Biomed Res Int; 2021; 2021():8864436. PubMed ID: 33860055
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of CDT1 as a prognostic marker in human lung adenocarcinoma using bioinformatics approaches.
    Jiang J; Zhang Y; Wang J; Yang X; Ren X; Huang H; Wang J; Lu J; Zhong Y; Lin Z; Lin X; Jia Y; Lin S
    PeerJ; 2023; 11():e16166. PubMed ID: 37790630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.